Literature DB >> 1667783

Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent.

R Wise1, J Johnson, N O'Sullivan, J M Andrews, B P Imbimbo.   

Abstract

The pharmacokinetics of rufloxacin after a single 400 mg oral dose were studied in eight volunteers, measuring plasma, inflammatory fluid and urine concentrations. Mean peak plasma concentrations of 4.4 mg/L were achieved at a mean time of 1.9 h after administration. The mean plasma elimination half-life was 28.2 h. Mean peak levels in inflammatory fluid reached 3.2 mg/L after 3.5 h, and 30.7% of the dose was eliminated in urine by 96 h. The apparent mean volume of distribution of rufloxacin, at steady state, was 109.5 L. The mean percentage penetration of rufloxacin into the inflammatory exudate, as measured by ratios of AUC0-50 h was 90%.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1667783     DOI: 10.1093/jac/28.6.905

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Penetration of rufloxacin into the cerebrospinal fluid in patients with inflamed and uninflamed meninges.

Authors:  M V Moretti; S Pauluzzi; M Cesana
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

2.  Pharmacodynamic effects of subinhibitory concentrations of rufloxacin on bacterial virulence factors.

Authors:  P C Braga; M T Sala; M Dal Sasso
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 3.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.

Authors:  L Aguilar; I P Balcabao; P Salvá; M Martín; J Costa; J Prieto; R Dal-ré
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

Authors:  P M Furneri; G Bisignano; G Cerniglia; G Nicoletti; M Cesana; G Tempera
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

6.  A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis.

Authors:  Emilia Ghelardi; Arianna Tavanti; Paola Davini; Francesco Celandroni; Sara Salvetti; Eva Parisio; Enrico Boldrini; Sonia Senesi; Mario Campa
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Biliary excretion of rufloxacin in humans.

Authors:  G Privitera; G Nicastro; B P Imbimbo; M Cesana; M Visconti; F Lombardi; G Tagliabue; E Faleschini; F Colturani; P Franzini
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

8.  Randomized, double-blind comparison of single-dose regimens of rufloxacin and pefloxacin for acute uncomplicated cystitis in women. French Multicenter Urinary Tract Infection-Rufloxacin Group.

Authors:  A Jardin; M Cesana
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.

Authors:  S M Qadri; Y Ueno; G Postle; D Tullo; J San Pedro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

10.  Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations.

Authors:  G Del Río; F Dalet; L Aguilar; J Caffaratti; R Dal-Ré
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.